Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis

计划入组 131 人 · 首次发布于 2005 年 8 月 10 日

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

计划入组 12 人 · 首次发布于 2009 年 5 月 6 日

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

计划入组 5 人 · 首次发布于 2006 年 12 月 25 日

PR1 leukemia peptide vaccine

Alpha-1-proteinase inhibitor(Aralast, Glassia, Prolastin, Prolastin-C, Respreeza, Zemaira)

3CL proteinase inhibitor(Boji Medical)

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

tiakis Biotech's Tiprelestat Receives FDA Support for Phase II PAH Trial

Tiprelestat Shows Promise in COVID-19 Patients: tiakis Biotech Announces Phase Ib/II Trial Results

Amgen's Tavneos Enters Phase 3 Trial for Pediatric ANCA-Associated Vasculitis